Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUCastle: Nintedanib treatment in Unicentric Castleman disease
2023-510253-42-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib in Castleman disease (CD), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Best metabolic response over 6 months. Planned start Jul 2024; status: authorised.
02
Drugs
nintedanib
03
Conditions
Castleman disease (CD)
Beyond the preview
Go deeper on 2023-510253-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510253-42-00.